- Home
- CRDF vs CRVO Comparison
CRDF vs CRVO Comparison
Compare CRDF & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDF
- CRVO
- Stock Information
- Founded
- CRDF 1999
- CRVO 2001
- Country
- CRDF United States
- CRVO United States
- Employees
- CRDF N/A
- CRVO N/A
- Industry
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- CRVO Biotechnology: Pharmaceutical Preparations
- Sector
- CRDF Health Care
- CRVO Health Care
- Exchange
- CRDF Nasdaq
- CRVO Nasdaq
- Market Cap
- CRDF 143.4M
- CRVO 160.4M
- IPO Year
- CRDF N/A
- CRVO N/A
- Fundamental
- Price
- CRDF $2.58
- CRVO $10.77
- Analyst Decision
- CRDF Strong Buy
- CRVO Strong Buy
- Analyst Count
- CRDF 3
- CRVO 5
- Target Price
- CRDF $9.33
- CRVO $57.60
- AVG Volume (30 Days)
- CRDF 1.1M
- CRVO 81.9K
- Earning Date
- CRDF 11-07-2024
- CRVO 11-12-2024
- Dividend Yield
- CRDF N/A
- CRVO N/A
- EPS Growth
- CRDF N/A
- CRVO N/A
- EPS
- CRDF N/A
- CRVO N/A
- Revenue
- CRDF $688,000.00
- CRVO $10,066,550.00
- Revenue This Year
- CRDF $15.00
- CRVO $54.67
- Revenue Next Year
- CRDF N/A
- CRVO N/A
- P/E Ratio
- CRDF N/A
- CRVO N/A
- Revenue Growth
- CRDF 49.57
- CRVO 116.29
- 52 Week Low
- CRDF $1.07
- CRVO $5.85
- 52 Week High
- CRDF $6.42
- CRVO $26.38
- Technical
- Relative Strength Index (RSI)
- CRDF 41.24
- CRVO 33.46
- Support Level
- CRDF $2.85
- CRVO $11.95
- Resistance Level
- CRDF $4.38
- CRVO $12.35
- Average True Range (ATR)
- CRDF 0.45
- CRVO 1.04
- MACD
- CRDF -0.10
- CRVO -0.16
- Stochastic Oscillator
- CRDF 2.70
- CRVO 7.45
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").
About CRVO CervoMed Inc.
CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.